Your browser doesn't support javascript.
loading
Tacrolimus After rATG and Infliximab Induction Immunosuppression-RIMINI Trial.
Viklicky, Ondrej; Zahradka, Ivan; Bold, Gantuja; Bestard, Oriol; Hruba, Petra; Otto, Natalie M; Stein, Maik; Sefrin, Anett; Modos, Istvan; Meneghini, Maria; Crespo, Elena; Grinyo, Josep; Volk, Hans-Dieter; Christakoudi, Sofia; Reinke, Petra.
Afiliação
  • Viklicky O; Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Zahradka I; Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Bold G; Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Bestard O; Department of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies (BeCAT), Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany.
  • Hruba P; Department of Nephrology and Kidney Transplantation, Vall d'Hebron University Hospital, Barcelona Hospital Campus, Barcelona, Spain.
  • Otto NM; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona, Spain.
  • Stein M; Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Sefrin A; Department of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies (BeCAT), Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany.
  • Modos I; Department of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies (BeCAT), Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany.
  • Meneghini M; Department of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies (BeCAT), Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany.
  • Crespo E; Information Technology Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Grinyo J; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona, Spain.
  • Volk HD; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona, Spain.
  • Christakoudi S; Department of Medicine, Barcelona University, Barcelona, Spain.
  • Reinke P; Berlin Center for Advanced Therapies (BeCAT) and Institute of Medical Immunology, Charité Universitätsmedizin Berlin, Berlin Institut of Health Center of Regenerative Therapies (BCRT), Berlin Institute of Health, Berlin, Germany.
Transplantation ; 108(1): 242-251, 2024 Jan 01.
Article em En | MEDLINE | ID: mdl-37525369
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tacrolimo / Soro Antilinfocitário Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Revista: Transplantation Ano de publicação: 2024 Tipo de documento: Article País de afiliação: República Tcheca
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tacrolimo / Soro Antilinfocitário Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Revista: Transplantation Ano de publicação: 2024 Tipo de documento: Article País de afiliação: República Tcheca